Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2011-10-06 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Details of Company Address 1 page 23.3KB
Regulatory Filings Classification · 95% confidence The document text is very short (497 characters) and contains only information about a change in the registered office address of the company. There is no financial data, no mention of reports, no regulatory filings, or any other detailed corporate information. This is an announcement related to company administrative details, specifically the registered office address change. Such announcements typically fall under Regulatory Filings (RNS) as they do not fit into more specific categories like management changes (MANG) or capital changes (SHA). Therefore, the best classification is Regulatory Filings (RNS).
2011-10-06 English
Full Year Statutory Accounts 51 pages 465.1KB
Annual Report Classification · 100% confidence The document is titled 'Phylogica Limited Financial Report 30 June 2011' and contains detailed sections typical of an annual report, including Directors' Report, Auditor's Independence Declaration, comprehensive financial statements (Statement of Comprehensive Income, Statement of Financial Position, Statement of Cash Flows, Statement of Changes in Equity), Notes to the Financial Statements, Directors' Declaration, Independent Auditor's Report, Corporate Governance Statement, and ASX additional information. The content includes detailed financial results, operating results, principal activities, directors' biographies, and corporate governance information. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. The fiscal period covered is the full year ended 30 June 2011. These characteristics align with the definition of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2011
2011-09-26 English
Appendix 3B 7 pages 160.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new ordinary shares, including the number of securities issued, terms, issue price, purpose, and dates related to the securities. It also includes sections about quotation of securities on the ASX (Australian Securities Exchange). This type of document is a formal announcement related to capital raising and issuance of new shares, which fits the category of Capital/Financing Update (CAP). It is not a full financial report, earnings release, or regulatory filing, but specifically an announcement about new securities issuance and quotation application.
2011-09-04 English
Change of Director`s Interest Notice 2 pages 117.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares/options held before and after the change, nature of the interest, and dates of changes. This is a clear report of personal share transactions by a company director. The document length is 3744 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or other report type. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2011-08-31 English
Change of Director`s Interest Notice 2 pages 119.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, nature of the change, and dates. This type of document is a formal notification of personal share transactions by a company director. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3844 characters, consistent with a detailed but concise insider transaction report.
2011-08-31 English
Broker Research Report 1 page 34.7KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Phylogica Ltd about a new research report prepared by RBS Morgans. It states that the report is available on the company website but does not contain the report itself or any financial data. The document length is only 2526 characters, which is quite short and consistent with an announcement rather than a full report. There is no indication of financial statements, management discussion, or detailed analysis. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the availability of a research report, not the report itself or a financial filing.
2011-08-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.